

## **Digital Therapeutic - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)**

Market Report | 2025-06-01 | 110 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

Digital Therapeutic Market Analysis

The digital therapeutic devices market is currently valued at USD 9.96 billion in 2025 and is forecast to reach USD 31.45 billion by 2030, advancing at a 25.86% CAGR. Expansion rests on software-based therapies that complement drugs, deliver measurable outcomes, and integrate smoothly with established clinical pathways. Regulatory harmonization-most notably the alignment between the United States Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS)-adds commercial certainty, while Germany's Digital Healthcare Act provides a blueprint for Europe. Artificial intelligence (AI) drives hyper-personalization, lifting patient engagement and clinical performance. At the same time, chronic-disease prevalence, maturing mobile infrastructure, and venture funding sustain demand, and payers are unlocking adoption by introducing reimbursement codes for mental-health digital therapies. Competitive intensity is steadily rising as large health-technology firms and pharmaceutical companies absorb niche developers, broadening therapeutic scope and bolstering distribution.

Global Digital Therapeutic Market Trends and Insights

Rising Burden of Chronic Diseases

Escalating rates of diabetes, asthma, chronic obstructive pulmonary disease, and cardiovascular disorders sustain continuous-care requirements that episodic clinical visits cannot satisfy. AI-driven digital twins helped 89% of users lower HbA1c below 7% within 12 months, underscoring clinical effectiveness in diabetes management. Chronic diseases absorb roughly 90% of

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

developed-market spending, sharpening the argument for cost-saving, always-on digital therapies that curb emergency visits and hospitalizations. Respiratory-care applications with smart inhalers improve adherence and trim exacerbations, as documented in real-world studies. Demographic aging further heightens demand for intuitive self-management tools that operate across smartphones, wearables, and connected sensors.

#### Rapid Mobile & Cloud Technology Maturation

The arrival of 5G, edge computing, and advanced mobile chipsets lets therapeutic algorithms run locally, erasing latency and guarding privacy. Wearable AI built on soft microelectronics now processes data on-device, making continuous therapy unobtrusive and responsive. Mature cloud architectures synchronize information across gadgets and electronic health-record platforms via standard FHIR-based APIs, yielding a single longitudinal patient view that refines decision support. App-store validation programs dedicated to health applications create vetted distribution routes that reassure clinicians and reassure patients.

#### Data-Security Concerns & Clinician Resistance

Rising cyber-incidents erode trust among physicians and patients, especially when therapies require constant behavioral and physiologic monitoring. European regulators caution that perpetual data flows create heightened breach risk. Liability worries persist because algorithmic suggestions influence medical decisions without clear fault lines when outcomes falter. Privacy-preserving encryption offers a path forward but is costly and computationally heavy, slowing deployment.

Other drivers and restraints analyzed in the detailed report include:

Reimbursement Expansion by Payers / AI-Driven Hyper-Personalization Boosting Engagement / High Development & Validation Costs /

For complete list of drivers and restraints, kindly check the Table Of Contents.

#### Segment Analysis

Software-only solutions generated 71.24% of digital therapeutic devices market revenue in 2024, reflecting the healthcare sector's inclination toward low-overhead deployments that blend seamlessly with existing clinical infrastructure. The segment's lead also stems from rapid update cycles, enabling developers to push algorithm refinements without hardware recalls. Virtual-reality and gaming products hold the highest CAGR outlook at 28.56% to 2030, buoyed by immersive environments that elevate patient motivation and deliver exposure therapy with controlled stimuli. Connected peripherals-smart inhalers, glucose monitors, and VR headsets-anchor ecosystem convergence, as platform-as-a-service models supply unified data pipelines that simplify analytics. This progression indicates that sustained leadership will belong to vendors offering end-to-end frameworks, not individual point solutions.

The digital therapeutic devices market size for software platforms is projected to increase as electronic-health-record integration improves, while the hardware-linked segment commands a growing premium for conditions needing biometric feedback. Interoperability, powered by open APIs, mitigates earlier fragmentation and encourages hospitals to consolidate multiple therapeutic lines on single dashboards, reducing vendor fatigue and improving clinician acceptance.

Treatment applications accounted for 73.46% of digital therapeutic devices market share in 2024 thanks to established reimbursement routes and clear diagnostic triggers. Clinicians view treatment-oriented software as a direct substitute or adjunct for pharmaceuticals, expediting prescription within familiar workflows. Preventive solutions-ranging from diabetes-risk programs

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

to migraine prophylaxis-are advancing at 27.73% CAGR, propelled by value-based care models that reward early intervention. FDA clearance of CT-132 marked the first preventive prescription digital therapeutic for episodic migraine, raising confidence among both payers and providers.

As health systems shift toward capitation and shared savings, preventive digital therapeutics become strategic levers for bending cost curves. Corporate wellness contracts further accelerate preventive uptake, granting developers alternative revenue outside insurer channels. The digital therapeutic devices market size for preventive programs is therefore poised to compound faster than the treatment segment beyond 2027, even though absolute value remains smaller through the forecast horizon.

The Digital Therapeutics Market Report is Segmented by Product Type (Software-Only Digital Therapeutics, Connected Devices and More), Therapeutic Area (Preventive [Pre-Diabetes, Obesity and More] and Treatment [Diabetes and More]), Modality (Standalone Prescription DTx, Dtx + Drug Combination and More), End User (Patients, Providers / Hospitals and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

## Geography Analysis

North America generated 46.78% of 2024 sales, with U.S. leadership rooted in FDA clarity, CMS reimbursement, and an investment ecosystem willing to fund late-stage trials. The launch of three mental-health billing codes in 2025 vaulted digital interventions into mainstream benefit design, driving swift integration across health plans. Canada and Mexico contribute incremental growth as cross-border telehealth collaborations expand.

Asia-Pacific is projected to be the fastest-advancing territory at 27.89% CAGR through 2030. Japan pioneered regulatory models that recognize software as therapy, prompting domestic pharma to co-develop digital interventions for neurological disorders. China leverages expansive mobile-payment adoption and urban telehealth portals to scale chronic-disease programs, while India's smartphone surge delivers low-cost behavioral-health applications to remote populations. Australia and South Korea act as test beds for advanced VR and AI algorithms due to high broadband penetration.

Europe shows measured but steady progress under the Medical Device Regulation, which harmonizes classification and post-market vigilance requirements. Germany's DiGA pathway covers more than 74 million insured lives and provides a practical reimbursement precedent that other member states increasingly emulate. France, Italy, and Spain integrate national-health-service pilots, whereas the United Kingdom refines NICE appraisal processes for software therapies. Strict data-protection rules fuel innovation in privacy-preserving analytics, differentiating European vendors on security credentials.

## List of Companies Covered in this Report:

2Morrow Inc. / Akili Interactive Labs / Better Therapeutics / Big Health / Biofourmis / Canary Health / Click Therapeutics / Cognoa / DarioHealth / Happify Health / Kaia Health / Koninklijke Philips / Livongo (Teladoc Health) / MindMaze / Noom Inc. / Omada Health / Pear Therapeutics / Propeller Health / Sword Health / Twine Health / Virta Health / WellDoc /

## Additional Benefits:

<ul> The market estimate (ME) sheet in Excel format /  
3 months of analyst support / </ul>

## Table of Contents:

1 Introduction  
1.1 Study Assumptions and Market Definition

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

## 1.2 Scope of the Study

## 2 Research Methodology

## 3 Executive Summary

## 4 Market Landscape

### 4.1 Market Overview

### 4.2 Market Drivers

#### 4.2.1 Rising Burden Of Chronic Diseases

#### 4.2.2 Rapid Mobile & Cloud Technology Maturation

#### 4.2.3 Government-Backed Preventive-Care Initiatives & VC Funding

#### 4.2.4 Reimbursement Expansion By Payers

#### 4.2.5 AI-Driven Hyper-Personalisation Boosting Engagement

#### 4.2.6 Corporate Well-Being Budgets Shifting To Prescription DTx

### 4.3 Market Restraints

#### 4.3.1 Data-Security Concerns & Clinician Resistance

#### 4.3.2 High Development & Validation Costs

#### 4.3.3 Limited Long-Term Clinical-Outcome Evidence

#### 4.3.4 Algorithmic Bias Triggering Regulatory Scrutiny

### 4.4 Value / Supply-Chain Analysis

### 4.5 Regulatory Landscape

### 4.6 Technology Outlook

### 4.7 Porter's Five Forces Analysis

#### 4.7.1 Bargaining Power of Suppliers

#### 4.7.2 Bargaining Power of Buyers

#### 4.7.3 Threat of New Entrants

#### 4.7.4 Threat of Substitutes

#### 4.7.5 Intensity of Competitive Rivalry

## 5 Market Size and Growth Forecasts (Value-USD)

### 5.1 By Product Type

#### 5.1.1 Software-only Digital Therapeutics

#### 5.1.2 Connected Devices (smart inhalers, CGMs, VR headsets)

#### 5.1.3 Platform-as-a-Service / APIs

### 5.2 By Therapeutic Area

#### 5.2.1 Preventive

##### 5.2.1.1 Pre-diabetes

##### 5.2.1.2 Obesity

##### 5.2.1.3 Smoking Cessation

##### 5.2.1.4 Others

#### 5.2.2 Treatment

##### 5.2.2.1 Diabetes

##### 5.2.2.2 Cardiovascular Diseases

##### 5.2.2.3 Neurological Disorders

##### 5.2.2.4 Respiratory Diseases

##### 5.2.2.5 Oncology Support

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.2.6 Others
- 5.3 By Modality
  - 5.3.1 Standalone Prescription DTx
  - 5.3.2 DTx + Drug Combination (e.g., inhaled therapies)
  - 5.3.3 Virtual-Reality / Gaming-based DTx
- 5.4 By End User
  - 5.4.1 Patients (D2C)
  - 5.4.2 Providers / Hospitals
  - 5.4.3 Payers & Insurers
  - 5.4.4 Employers & Corporate Wellness Programs
- 5.5 By Geography
  - 5.5.1 North America
    - 5.5.1.1 United States
    - 5.5.1.2 Canada
    - 5.5.1.3 Mexico
  - 5.5.2 Europe
    - 5.5.2.1 Germany
    - 5.5.2.2 United Kingdom
    - 5.5.2.3 France
    - 5.5.2.4 Italy
    - 5.5.2.5 Spain
    - 5.5.2.6 Rest of Europe
  - 5.5.3 Asia-Pacific
    - 5.5.3.1 China
    - 5.5.3.2 Japan
    - 5.5.3.3 India
    - 5.5.3.4 Australia
    - 5.5.3.5 South Korea
    - 5.5.3.6 Rest of Asia-Pacific
  - 5.5.4 Middle East and Africa
    - 5.5.4.1 GCC
    - 5.5.4.2 South Africa
    - 5.5.4.3 Rest of Middle East and Africa
  - 5.5.5 South America
    - 5.5.5.1 Brazil
    - 5.5.5.2 Argentina
    - 5.5.5.3 Rest of South America

## 6 Competitive Landscape

### 6.1 Market Concentration

### 6.2 Market Share Analysis

6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)

#### 6.3.1 2Morrow Inc.

#### 6.3.2 Akili Interactive Labs

#### 6.3.3 Better Therapeutics

#### 6.3.4 Big Health

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.5 Biofourmis
- 6.3.6 Canary Health
- 6.3.7 Click Therapeutics
- 6.3.8 Cognoa
- 6.3.9 DarioHealth
- 6.3.10 Happify Health
- 6.3.11 Kaia Health
- 6.3.12 Koninklijke Philips NV
- 6.3.13 Livongo (Teladoc Health)
- 6.3.14 MindMaze
- 6.3.15 Noom Inc.
- 6.3.16 Omada Health
- 6.3.17 Pear Therapeutics
- 6.3.18 Propeller Health
- 6.3.19 Sword Health
- 6.3.20 Twine Health
- 6.3.21 Virta Health
- 6.3.22 WellDoc Inc.

## 7 Market Opportunities and Future Outlook

### 7.1 White-Space and Unmet-Need Assessment

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Digital Therapeutic - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)**

Market Report | 2025-06-01 | 110 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com



**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)